Floatz logo

Rituximab

Adult T-Cell Leukemia/Lymphoma

Northwestern Universitymonoclonal_antibodyPhase 2Dormant
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the Adult T-Cell Leukemia/Lymphoma cohort.

Asset / SponsorPhaseRating
Dexasone
The First Affiliated Hospital of Soochow University
Phase 2BBB
Fludarabine
John Reneau
Phase 2BBB
Cyclophosphamide
John Reneau
Phase 4BBB
Etoposide
National Cancer Institute (NCI)
Phase 2BBB
LENALIDOMIDE
National Cancer Institute (NCI)
Phase 2BBB

View all 50 →

Same molecule, other indications

Rituximab is also rated in:

lymphoblastic lymphomaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
grade III lymphomatoid granulomatosisDormant
BBB
Indicative · Phase 2
74 / 100
View asset →
testicular lymphomaDormant
BBB
Indicative · Phase 2
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →